For the year ending 2025-12-31, ADCT made $81,357K in revenue. -$142,623K in net income. Net profit margin of -175.31%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue, net | 81,357 | 70,837 | ||
| Cost of product sales | 5,798 | 5,949 | ||
| Research and development | 104,005 | 109,633 | ||
| Selling and marketing | 43,374 | 44,015 | ||
| General and administrative | 36,559 | 41,894 | ||
| Restructuring, impairment and other related costs | 13,120 | - | ||
| Total operating expense | 202,856 | 201,491 | ||
| Loss from operations | -121,499 | -130,654 | ||
| Interest income | 8,810 | 12,272 | ||
| Deferred royalty obligation interest expense | 35,346 | - | ||
| Effective interest expense on senior secured term loan facility | 16,275 | - | ||
| Other interest expense | 12 | - | ||
| Interest expense | 51,633 | 50,211 | ||
| Other, net | 22,714 | 12,457 | ||
| Total other expense, net | -20,109 | -25,482 | ||
| Loss before income taxes | -141,608 | -156,136 | ||
| Income tax expense | 1,015 | 166 | ||
| Loss before equity in net losses of joint venture | -142,623 | -156,302 | ||
| Equity in net losses of joint venture | 0 | -1,544 | ||
| Net loss | -142,623 | -157,846 | ||
| Basic EPS | -1.12 | -1.62 | ||
| Diluted EPS | -1.12 | -1.62 | ||
| Basic Average Shares | 127,067,540 | 97,159,966 | ||
| Diluted Average Shares | 127,067,540 | 97,159,966 | ||
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)